Structural requirements of acetylcholinesterase reactivators

Mini-Reviews in Medicinal Chemistry

Volumn 6, Issue 3, 2006, Pages 269-277

  Kuca, Kamil ^a   Jun, Daniel ^a   Musilek, Kamil ^b  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Acetylcholinesterase; Antidote; Nerve agent; Pesticide; Reactivator; Structural requirements

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 1 (4 HYDROXYIMINOMETHYLPYRIDINIUM) 3 (4 CARBAMOYLPYRIDIUM)PROPANEDIBROMIDE; 1,1' METHYLENEBIS(4 HYDROXYIMINOMETHYLPYRIDINIUM) DICHLORIDE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANTIDOTE; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE REACTIVATOR; K 048; K 074; K 075; METHOXIME; MMC 4; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; OBIDOXIME; ORGANOPHOSPHORUS COMPOUND; OXIME DERIVATIVE; PESTICIDE; PRALIDOXIME; TO 052; TO 055; TO 057; TO 058; TRIMEDOXIME; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; INTOXICATION; NONHUMAN; REVIEW;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; ANTIDOTES; ATROPINE; BINDING SITES; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; ENZYME ACTIVATION; HUMANS; MUSCARINIC ANTAGONISTS; NEUROTRANSMITTER AGENTS; NICOTINE; OXIMES; PHOSPHORYLATION; RECEPTOR, MUSCARINIC M1;

EID: 33646056667     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955706776073510     Document Type: Review

References (55)

1. Patocka, J., Kuca K., Jun, D. Acta Medica (Hradec Kralove), 2004, 47, 215.
2. Zajtchuk, R., Bellamy, R.F. Medical aspects of chemical and biological warfare, The Office of the Surgeon General at TMM Publications, Boden Institute; Walter Reed Army Medical Center; Washinghton D.C., United states of America, 1997.
3. Bajgar, J. Adv. Clin. Chem., 2004, 38, 151.
4. Marrs, T.C. Pharmacol. Therap., 1993, 58, 51.
5. Taylor, P. Anticholinergic agents. The Pharmacological Basis of Therapeutics. McGraw Hill: New York, 1996.
6. Kassa, J. J. Toxicol. Clin. Toxicol., 2002, 40, 803.
7. Koplovitz, I., Stewart, J.R. Drug. Chem. Toxicol., 1992, 15, 117.
8. Shih, T.M. Arch. Toxicol., 1993, 67, 637.
9. Woodard, C.L., Lukey, B.J. Drug. Metab. Dispos., 1991, 19, 283.
10. Worek, F., Klimmek, R., Szinicz, L. Drug Chem Toxicol., 1995, 18, 137.
11. Thiermann, H., Radtke, M., Spohrer, U., Klimmek, R., Eyer, P. Arch. Toxicol., 1996, 70, 293.
12. Cabal, J., Kuca, K., Kassa, J. Bas. Clin. Pharmacol. Toxicol., 2004, 95, 81.
13. Kassa, J. Acta Medica (Hradec Kralove), 2005, 48, 87-90.
14. Kassa, J. Neurotox. Res., 2005. (in Press)
15. Kuca, K., Bielavsky, J., Cabal, J., Kassa, J. Bioorg. Med. Chem. Lett., 2003, 13, 3545.
16. Kuca, K., Kassa, J. J. Enzyme Inhib. Med. Chem. 2003, 18, 529.
17. Patocka, J., Cabal, J., Kuca, K., Jun, D. J. Appl. Biomed., 2005, 3, 91.
18. Chennamaneni, S.R., Vobalaboina, V., Garlapati, A. Bioorg. Med. Chem. Lett., 2005, 15, 3076.
19. Kim, T.H., Kuca, K., Jun, D, Jung, Y.S. Bioorg. Med. Chem. Lett., 2005, 15, 2914.
20. Picha, J., Kuca, K., Kivala, M., Kohout, M., Cabal, J., Liska, F. J. Enzyme Inhib. Med. Chem., 2005, 20, 233.
21. Yang, G.Y., Yoon, J.H., Seong, C.M., Park, N.S., Jung, Y.S. Bull. Korean Chem. Soc., 2003, 24, 1368.
22. Pang, Y.P., Kollmeyer, T.M., Hong, F., Lee, J.C., Hammond, P.I., Haugabouk, S.P., Brimijoin, S. Chem. Biol., 2003, 10, 491.
23. Mager, P.P. Pharmazie, 1981, 36, 450.
24. Mager, P.P. Pharmazie 1983, 38, 271.
25. Mager, P.P., Weber, A. Drug Des. Dis., 2004, 18, 127.
26. Hammond, P.I., Kern, C., Hong, F., Kollmeyer, T.M., Pang, Y.P., Brimijoin, S. J. Pharmacol. Exp. Therap., 2003, 307, 190.
27. Dohnal, V., Kuca, K., Jun, D. J. Appl. Biomed., 2005 (In Press)
28. Stalc, A., Sentjurc, M. Biochem. Pharmacol., 1990, 40, 2511.
29. Whiteley, C.G., Ngwenya, D.S. Biochem. Mol. Biol. Int., 1995, 36, 1107.
30. Kuca, K., Cabal, J., Patocka, J., Dohnal, V. Lett. Drug Des. Disc., 2004, 1, 97.
31. Kassa, J. Ces. Slov. Farm., 1998, 1, 46.
32. Bajgar, J. Sbor. Ved. Pr. LFUK (Hradec Kralove), 1991, 34, 3.
33. Sakurada, K., Matsubara, K., Shimizu, K., Shiono, H., Seto, Y., Tsuge, K., Yoshino, M., Sakai, I., Mukoyama, H., Takatori, T. Neurochem. Res., 2003, 28, 1401
34. Kassa, J., Cabal, J. Pharm. Toxicol., 1999, 84, 41.
35. Kassa, J., Cabal, J. Hum. Exp. Toxicol., 1999, 18, 560.
36. Kuca, K., Kassa, J. Hum. Exp. Toxicol., 2004, 23, 167.
37. Patocka, J., Bielavsky J. Biochem. Pharmacol., 1972, 21, 742.
38. Kuca, K., Patocka, J., Cabal, J. J. Appl. Biomed, 2003, 1, 207.
39. Kuca, K., Cabal, J., Bajgar, J., Jun, D. Lett. Drug Des. Disc., 2005, 2, 23.
40. Kuca, K., Cabal, J. Toxicol. Mech. Methods, 2005, 15, 247.
41. Kuca, K., Patocka, J. J. Enzyme Inhib. Med. Chem., 2004, 19, 39.
42. Musilek, K., Kuca, K., Jun, D., Dohnal, V., Dolezal, M. J. Enzyme Inhib. Med. Chem., 2005, 20, 409.
43. Musilek, K., Kuca, K., Jun, D., Dohnal, V., Dolezal, M. Biorg. Med. Chem. Lett., 2005, (in press).
44. Heath, D.F.: Organophosphorus Poisons: Anticholinesterases and related compounds. Pergamon Press, Oxford, 1961.
45. Cabal, J., Kuca, K., Jun, D., Bajgar, J., Hrabinova, M. Ces. Slov. Farm., 2005, 54, 192 (In Czech).
46. Kuca, K., Picha, J., Cabal, J., Liska F. J. Appl. Biomed., 2004, 2, 51.
47. Worek, F., Kirchner, T., Backer, M., Szinicz, L. Arch. Toxicol., 1996, 70, 497.
48. Worek, F., Diepold, C., Eyer, P. Arch. Toxicol., 1999, 73, 7.
49. Worek, F., Widmann, R., Knopff, O., Szinicz, L. Arch. Toxicol., 1998, 72, 237.
50. Cabal, J., Hampl, F., Liska, F., Patocka, J., Riedl, F., Sevcikova, K. Coll. Czech Chem. Commun., 1998, 63, 1021.
51. Worek F., Eyer P., Szinicz L. Arch. Toxicol., 1998, 72, 580.
52. Clement J.G. Arch. Tocicol., 1992, 66, 143.
53. De Jong L.P.A., Wolring G.Z. Biochem. Pharmacol., 1978, 27, 2229.
54. Clement J.G., Shiloff J.D., Gennings C. Arch. Toxicol., 1987, 61, 70.
55. Puu G., Artursson E., Bucht G. Biochem. Pharmacol., 1986, 35, 1505.